Abstract
Tafolecimab (SINTBILO®), a subcutaneously administered anti-proprotein convertase subtilisin/kexin type 9 enzyme (PCSK9) monoclonal antibody, is being developed by Innovent for the treatment of hypercholesterolemia and mixed hyperlipidemia. Tafolecimab was approved in August 2023 in China as an adjunct to diet, in combination with a statin or statin with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, for the treatment of adults with primary hyperlipidemia [including heterozygous familial hypercholesterolemia (HeFH) and non-familial hypercholesterolemia (non-FH)] and mixed dyslipidemia who have failed to achieve LDL-C goals despite moderate or higher doses of statins, to reduce LDL-C, total cholesterol (TC), and apolipoprotein B (ApoB) levels. This article summarizes the milestones in the development of tafolecimab leading to this first approval for the treatment of adults with primary hyperlipidemia and mixed dyslipidemia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143.
Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9–119.
Li JJ, Zhao SP, Gao RL, on behalf of the Joint Committee on the Chinese Guidelines for Lipid Management. Chinese guidelines for lipid management (2023). Chin J Cardiol. 2023;51(3):221–55.
Li JJ. Tafolecimab, a novel member of PCSK9 monoclonal antibodies, is worth expecting in a Chinese population. JACC Asia. 2023;3(4):646–8.
Hess CN, Low Wang CC, Hiatt WR. PCSK9 inhibitors: mechanisms of action, metabolic effects, and clinical outcomes. Annu Rev Med. 2018;69:133–45.
Innovent. Tafolecimab: Chinese prescribing information. 2023. https://www.innoventbio.com/. Accessed 11 Sep 2023.
Innovent. Innovent announces the NMPA approval of SINTBILO® (tafolecimab injection) for the treatment of adult patients with primary hypercholesterolemia and mixed dyslipidemia [media release]. 16 August 2023. https://www.innoventbio.com/.
National Medical Products Administration. The State Drug Administration approves tafolecimab injection for marketing. 2023. https://www.nmpa.gov.cn/yaowen/ypjgyw/20230816171810151.html. Accessed 11 Sep 2023.
Cui Y, Zhao X, Qi L, et al. A potential long-acting LDL-cholesterol-lowering PCSK9 monoclonal antibody: randomized, placebo-controlled phase 1 studies. JACC Asia. 2021;1(3):411–5.
Huo Y, Li Y, Zhang P, et al. Efficacy and safety of tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial [abstract no. 10111]. Circulation. 2022;146(Suppl_1).
Chai M, He Y, Zhao W, et al. Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2). BMC Med. 2023;21(77):1–11.
Qi L, Liu D, Qu Y, et al. Tafolecimab in Chinese patients with hypercholesterolemia (CREDIT-4): a randomized, double-blind, placebo-controlled phase 3 trial. JACC Asia. 2023;3(4):636–45.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability
Not applicable.
Additional information
This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Keam, S.J. Tafolecimab: First Approval. Drugs 83, 1545–1549 (2023). https://doi.org/10.1007/s40265-023-01952-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-023-01952-y